Avadel Pharmaceuticals plc
AVDL•NASDAQ•Healthcare•Drug Manufacturers - Specialty & Generic

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.avadel.com
Phone353 1 901 5201
Address
10 Earlsfort Terrace Dublin, D02 T380 Ireland

Corporate Identifiers

CIK0001012477
CUSIP05337M104
ISINIE00BDGMC594
SIC2834

Leadership Team & Key Executives

Gregory J. Divis Jr.
Chief Executive Officer and Director
Thomas S. McHugh
Senior Vice President, Principal Financial and Accounting Officer and Chief Financial Officer
Jerad G. Seurer
General Counsel, Company Secretary and Compliance Officer
Susan Rodriguez
Chief Operating Officer
Gregory J. Davis
Vice President of Corporate and Business Development
Angie Woods
Vice President of People and Culture
Dr. Jason M. Vaughn Ph.D., R.Ph.
Senior Vice President of Technical Operations
Jennifer Gudeman PharmD
Senior Vice President of Medical and Clinical Affairs
Dr. Polly A. Murphy D.V.M., M.B.A., Ph.D.
Chief Business Officer
Marla Scarola M.S.
Senior Vice President of Regulatory and Quality